Because SGLT-2 inhibitors enhance glucose management, body weight, and blood pressure, they may improve the prognosis of individuals with T2DM who have concurrent NAFLD [28]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.